BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaweme NM, Zhou F. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment. Front Immunol 2021;12:683381. [PMID: 34220833 DOI: 10.3389/fimmu.2021.683381] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Serroukh Y, Hébert J, Busque L, Mercier F, Rudd CE, Assouline S, Lachance S, Delisle JS. Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. Blood Rev 2023;57:100991. [PMID: 35941029 DOI: 10.1016/j.blre.2022.100991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Sabbah M, Jondreville L, Lacan C, Norol F, Vieillard V, Roos-Weil D, Nguyen S. CAR-NK Cells: A Chimeric Hope or a Promising Therapy? Cancers (Basel) 2022;14:3839. [PMID: 35954502 DOI: 10.3390/cancers14153839] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Boyd-gibbins N, Karagiannis P, Hwang DW, Kim S. iPSCs in NK Cell Manufacturing and NKEV Development. Front Immunol 2022;13:890894. [DOI: 10.3389/fimmu.2022.890894] [Reference Citation Analysis]
4 Yu G, Lu W, Chen X, Li Y, Long J, Zheng Z, Yin C, Xu D. Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission. Leuk Lymphoma 2022;:1-12. [PMID: 35695125 DOI: 10.1080/10428194.2022.2086243] [Reference Citation Analysis]
5 Brauneck F, Seubert E, Wellbrock J, Schulze Zur Wiesch J, Duan Y, Magnus T, Bokemeyer C, Koch-Nolte F, Menzel S, Fiedler W. Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML. Int J Mol Sci 2021;22:12919. [PMID: 34884723 DOI: 10.3390/ijms222312919] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]